Product Images Valsartan And Hydrochlorothiazide

This text contains information about blood pressure readings in mmHg for a study or clinical trial involving Valsartan-HCTZ 320/125 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo. The baseline SBP levels are listed from 140 to 180 mmHg. Information regarding SBP targets below 140 mmHg is also mentioned.*

This text provides information on the blood pressure medication Valsartan-HCTZ 320/25 mg and placebo with respective baseline diastolic blood pressure (DBP) values. The DBP target is set at less than 90 mmHg, with the initial DBP value recorded at 105 mmHg.*

This text seems to be a table showing blood pressure levels corresponding to different medications and a placebo. It appears to be comparing the effect of Valsartan-HCTZ 320/25 mg, Valsartan 320 mg, Hydrochlorothiazide 25 mg, and Placebo on blood pressure (SBP – systolic blood pressure) measurements. The table shows baseline SBP levels and subsequent readings at 140, 145, 150, 155, 160, 165, and 170 mmHg.*

This text mentions different blood pressure values and medication dosages for Valsartan-HCTZ, Valsartan, Hydrochlorothiazide, and Placebo. Baseline diastolic blood pressure is also referenced.*

This text provides information about a medication containing 160 mg of Valsartan USP and 25 mg of Hydrochlorothiazide USP in each tablet. The National Drug Code (NDC) for this specific tablet is 71335-2633-1. It recommends storing the tablets at a temperature between 20°C to 25°C with excursions allowed from 15°C to 30°C. The medication guide should be dispensed to each patient, and the tablets should be kept in tight containers and away from moisture. It also mentions the manufacturers as Bryant Ranch Prepack, Inc. and Zhejiang Huahai Pharmaceutical Co., Ltd.*